AI filing briefs · archive

8-K filings in October 2026, explained

3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

Clear

13 of 3,560 briefs match

newest first · times in ET
FIRYFiry Inc. Oct 5, 5:21 PM ET

Firy sells its Exit Games stake back to Exit Games for $55 million in cash

Positive m&a Written later 1.012.017.01

Firy Inc. agreed to sell its entire stake in Exit Games GmbH, about 10.5% of Exit Games' outstanding share capital, back to Exit Games for $55.0 million in cash. The transaction was completed on October 2, 2026, and Firy ceased to be a shareholder. Firy bought the stake for $50 million in July 2021, so the filing describes the sale as a cash return of approximately 1.1x the original investment.

  • Sale price: $55.0 million in cash, paid to Firy in full at closing on October 2, 2026
  • Original purchase price: $50 million in July 2021, under the former name Skillz Inc.
  • Firy ceased to be a shareholder of Exit Games; the 8-K states no revenue or profit effect
Read the filing on SEC.gov ↗
NRXPNRX Pharmaceuticals, Inc. Oct 5, 5:00 PM ET

NRx Pharmaceuticals unit wins $11.2 million DARPA contract for depression trial

Positive product/contract Written later 1.01

On September 29, 2026, subsidiary NRx Defense Systems entered a prime contract with DARPA to conduct the SPARC-TMS clinical trial, which pairs robotic transcranial magnetic stimulation with the investigational drug NRX-101 for treatment-resistant depression. The contract is valued at approximately $11.2 million, with about $6.7 million initially obligated, and the remainder depends on appropriations and DARPA's exercise of funding options.

  • Aggregate contract value of approximately $11.2 million; approximately $6.7 million initially obligated by DARPA.
  • 18-month performance period, with payment tied to achievement and acceptance of specified milestones.
  • Either party may terminate under certain circumstances, including if the program is determined unlikely to achieve its objectives.
  • Full contract terms to be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026.
Read the filing on SEC.gov ↗
NEONEOGENOMICS INC Oct 5, 4:08 PM ET

NeoGenomics names Warren Stone CEO effective Jan. 4, 2027; Q3 revenue about $209 million

Positive leadership Written later 2.025.025.03

NeoGenomics said its board chose President and COO Warren Stone as chief executive effective January 4, 2027, with current CEO Tony Zook becoming Executive Chairman. The company also reported preliminary, unaudited third quarter revenue of approximately $209 million and said full-year total revenue guidance is expected to increase at the midpoint, though the preliminary figures could change after quarter-end closing.

  • Warren Stone to become CEO effective January 4, 2027, with a base salary of $850,000 and a 100% target bonus
  • Preliminary Q3 2026 total revenue of approximately $209 million, with NGS revenue growth of approximately 28%
  • Full-year total revenue guidance expected to increase at the midpoint; adjusted EBITDA guidance reiterated from July 28, 2026
  • Board maximum size raised from 10 to 11 directors; Chair Lynn Tetrault steps down January 4, 2027 and will not stand for reelection in 2027
Read the filing on SEC.gov ↗
WORXSCWorx Corp. Oct 5, 1:08 PM ET

SCWorx Regains Nasdaq Listing Compliance; Reinstatement Date Not Yet Set

Positive legal/regulatory Written later 1.013.017.01

Nasdaq's Hearings Panel granted SCWorx's request for reconsideration on October 2, 2026, found the company compliant with continued listing requirements, and approved continued listing on The Nasdaq Capital Market. Trading on Nasdaq, suspended since April 14, 2026, will resume on a date Nasdaq has yet to schedule, and the stock trades on the OTCQB until then. The approval carries a one-year Panel Monitor through October 2, 2027, and the company's private placement investors waived termination rights tied to the earlier delisting decision, though those rights revive if the delisting takes effect.

  • On October 2, 2026, the Panel granted reconsideration of its September 17, 2026 delisting decision and approved continued listing on The Nasdaq Capital Market
  • Publicly held shares rose to 549,092 as of September 17, 2026, after the September 16, 2026 private placement of 350,000 shares and related warrants
  • Nasdaq trading has been suspended since April 14, 2026; the stock stays on the OTCQB under WORX until Nasdaq sets a reinstatement date
  • If all purchasers terminated their purchases, the company would have to return an aggregate of $938,000 and the placement shares and warrants would be cancelled
Read the filing on SEC.gov ↗
SBRSABINE ROYALTY TRUST Oct 5, 11:54 AM ET

Sabine Royalty Trust declares $0.355450 per unit October distribution, up from prior month

Positive shareholder Written later 2.02

Sabine Royalty Trust declared a monthly cash distribution of $0.355450 per unit, payable October 29, 2026, to unitholders of record on October 15, 2026. The trustee said the distribution is higher than the prior month's, mainly due to higher oil production and oil and gas prices, slightly offset by lower gas production. The filing does not state the prior month's per-unit amount.

  • Distribution of $0.355450 per unit, record date October 15, 2026, payable October 29, 2026
  • Oil volume of 45,391 barrels versus 39,647 barrels the prior month; oil price of $80.56 per barrel versus $79.10
  • Gas volume of 1,019,756 Mcf versus 1,094,091 Mcf the prior month; gas price of $2.34 per Mcf versus $2.33
  • About $436,000 of September revenue will be posted in October, and about $1,618,000 in revenue has been received since the September close
Read the filing on SEC.gov ↗

NeuroOne Reports Fiscal Q4 Revenue Up 38.4% to $3.8 Million, Record $4.5 Million Order

Positive earnings Written later 2.028.01

NeuroOne preliminarily reported fiscal fourth-quarter 2026 product revenue of approximately $3.8 million, up 38.4% from the prior-year quarter, and full-year revenue of approximately $10.5 million, up 15.6% and at the top of its guidance range. The company also disclosed a $4.5 million purchase order received in September 2026, which it describes as its largest ever, and open purchase orders of $5.4 million as of September 30, 2026. The figures are unaudited and subject to change, with final results due in December 2026.

  • Fiscal Q4 2026 product revenue of approximately $3.8 million, up 38.4% from approximately $2.7 million in Q4 2025.
  • Full-year fiscal 2026 revenue of approximately $10.5 million, up 15.6%, at the top of the previously announced $9.2 million to $10.5 million guidance range.
  • $4.5 million purchase order received in September 2026; about $1.0 million shipped by September 30, with the remaining $3.6 million expected to begin shipping in fiscal Q1 2027.
  • Open purchase orders totaled $5.4 million as of September 30, 2026; complete results are expected in December 2026 with the Form 10-K.
Read the filing on SEC.gov ↗
INTTINTEST CORP Oct 5, 8:39 AM ET

InTest expects record Q3 orders of $48 million to $50 million; revenue at high end of guidance

Positive earnings Written later 2.02

InTest said preliminary third-quarter 2026 orders are expected at $48 million to $50 million, a record driven by back-end semiconductor orders, and revenue is expected at the high end of its $33 million to $35 million guidance range. Backlog at September 30, 2026 is expected at $58 million to $60 million. The figures are preliminary and subject to the completion of financial closing procedures, and the company plans to report full third-quarter results on November 6, 2026.

  • Q3 2026 orders expected at $48 million to $50 million, up 28% to 33% from Q3 2025, led by record back-end semiconductor orders
  • Q3 revenue expected at the high end of the $33 million to $35 million guidance range, growth of more than 30% from $26.2 million in Q3 2025
  • Backlog at September 30, 2026 expected at $58 million to $60 million, up roughly 28% to 32% from $45.4 million at June 30, 2026
  • Full third-quarter results to be reported on November 6, 2026; figures are preliminary and may vary materially
Read the filing on SEC.gov ↗
AGPUAXE COMPUTE INC. Oct 5, 8:35 AM ET

Axe Compute Buys Georgia AI Cluster SPV From Duos, Repays $87.8 Million Loan

Positive m&a Written later 1.017.01

Axe Compute completed its acquisition of 100% of the entity that owns the 288-server Georgia AI cluster from Duos Technologies on September 30, 2026. The company paid off the entity's roughly $87.8 million asset-backed loan with no new equity issued, and owes Duos a remaining $42.9 million deferred purchase price. The customer agreement was extended from three to five years, and the company expects about $364.6 million in revenue over its life.

  • Acquisition closed September 30, 2026; the $87.8 million asset-backed loan was repaid in full with no new equity issued.
  • Remaining $42.9 million deferred purchase price is payable to Duos at $715,000 per month, due by the earlier of 12 months after signing or a financing secured by the cluster.
  • Customer agreement extended from three years to five years, running through 2031 with renewal options.
  • Duos covers colocation and energy costs for the five-year term; the company expects about $364.6 million in revenue over the agreement's life.
Read the filing on SEC.gov ↗
WULFTERAWULF INC. Oct 5, 8:21 AM ET

TeraWulf Raises Muskie Contracted Power to 1 GW and Moves Second Phase to 2029

Positive product/contract Written later 8.01

TeraWulf said its subsidiary signed amended and restated power agreements with Kentucky Power that raise contracted capacity at its Muskie Data Campus in Kentucky from 500 MW to 1 GW. The filing also says the second 500 MW phase is now planned for delivery in 2029 instead of 2030, subject to Kentucky Public Service Commission approval, and the company plans to seek more senior secured financing, with no assurance it will obtain it.

  • Contracted power at Muskie rises from 500 MW to 1 GW under agreements executed October 1, 2026.
  • Second 500 MW phase delivery moves from 2030 to 2029, subject to Kentucky Public Service Commission approval and Kentucky Power's construction schedule.
  • First 500 MW phase remains targeted to begin ramping in 2028.
  • TeraWulf plans to upsize its senior secured revolving credit facility and seek additional senior secured debt for letter of credit needs; the filing gives no assurance the financing will be obtained.
Read the filing on SEC.gov ↗

Stablecoin Development Corp SKY holdings rise to $180.2 million at September 30

Positive other Written later 2.028.01

Stablecoin Development Corp (SDEV) reported preliminary, unaudited figures for September 30, 2026 showing its SKY token holdings had a fair value of approximately $180.2 million, up from approximately $119.2 million at June 30, 2026. The filing does not report revenue or profit, and the company held only about $7.2 million in cash with no outstanding debt, so shareholder exposure is concentrated in the value of SKY.

  • SKY holdings of 2,321,079,862 tokens at September 30, 2026, valued at approximately $180.2 million using a SKY price of $0.07764
  • Fair value compared with approximately $119.2 million at June 30, 2026
  • Approximately 34.6 million SKY earned in staking rewards during the quarter, with no SKY sold to date
  • Approximately $7.2 million in cash and cash equivalents and no outstanding indebtedness at September 30, 2026
Read the filing on SEC.gov ↗
PCVXVaxcyte, Inc. Oct 5, 8:01 AM ET

Vaxcyte reports positive OPUS-1 Phase 3 topline data for VAX-31 pneumococcal vaccine

Positive product/contract Written later 7.018.01

Vaxcyte said its pivotal Phase 3 OPUS-1 adult trial met all prespecified primary endpoints for VAX-31, its 31-valent pneumococcal conjugate vaccine candidate, compared with Prevnar 20 and Capvaxive. The company said the results will serve as the cornerstone of a planned Biologics License Application to the FDA, with results from OPUS-2 and OPUS-3 expected in the first half of 2027. The filing contains no revenue, earnings or cash figures, and the data remain subject to FDA review.

  • All 28 VAX-31 serotypes shared with PCV20 and/or PCV21 met the noninferiority criterion in adults 50 and older.
  • VAX-31 met noninferiority for 20 of 20 serotypes shared with PCV20 and 17 of 19 shared with PCV21; serotypes 3 and 12F missed the stricter criterion against PCV21.
  • OPUS-2 and OPUS-3 results are expected in the first half of 2027, and a Biologics License Application submission is planned for the first half of 2028.
Read the filing on SEC.gov ↗
MTDRMatador Resources Co Oct 5, 7:36 AM ET

Matador closes $1.255 billion Paloma Permian acquisition in New Mexico

Positive m&a Written later 2.017.01

Matador Resources completed its acquisition of Paloma Permian LLC on October 1, 2026, paying $1.255 billion in cash, subject to post-closing adjustments. The company says the deal adds about 16,500 net acres in Eddy and Lea Counties, New Mexico, and over 156 net drilling locations, and expects it to support free cash flow and debt repayment.

  • Closed October 1, 2026, for $1.255 billion in cash, subject to post-closing adjustments
  • Adds about 16,500 net, mostly undeveloped acres in Eddy and Lea Counties, New Mexico
  • Adds over 156 net locations; Matador expects to begin drilling up to 25 wells by year-end 2027
  • Expects to pay down its PNC Bank-led credit facility by $350-400 million in Q4 2026, depending on commodity prices
Read the filing on SEC.gov ↗
PTCPTC INC. Oct 5, 7:22 AM ET

PTC agrees to be acquired by Schneider Electric for $205 per share in cash

Positive m&a Written later 1.017.01

PTC signed a merger agreement under which Schneider Electric will acquire the company for $205 per share in cash, valuing PTC's equity at approximately $22.6 billion. The price is a 42.3% premium to PTC's last closing price, and PTC shareholders must approve the deal; closing is anticipated by Q3 2027. Shareholders would receive cash and the stock would be delisted from Nasdaq if the merger closes.

  • Merger consideration: $205 per share in cash; implied enterprise value of $23.7 billion
  • Premium of 42.3% to last closing price and 46.1% to the previous 30-trading-day VWAP
  • Company must pay Schneider Electric a $700 million termination fee in specified circumstances
  • Closing anticipated by Q3 2027, subject to majority shareholder approval and regulatory clearances including HSR and CFIUS
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.